African swine fever virus ASFV-KOR.INJE.MEC-01.2022 attenuated by cell adaptation, and use thereof
The attenuated ASFV-KOR.INJE.MEC-2022 virus, developed through cellular adaptation, addresses the lack of effective ASF vaccines by offering a safe and effective vaccine composition and diagnostic tool, enhancing prevention and detection capabilities.
Patent Information
- Application Number
- PCT/KR2024/007169
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-27
- Publication Date
- 2024-12-05
AI Technical Summary
Current vaccines and treatments for African swine fever (ASF) are lacking, and the increasing global cases pose a significant challenge due to the virus's high mortality rate and limited vaccine development options, with no effective vaccine available worldwide.
Development of an attenuated African swine fever virus ASFV-KOR.INJE.MEC-2022 through cellular adaptation in a rhesus monkey kidney cell line, which is used to create a vaccine composition for prevention and a diagnostic kit, leveraging genetic deletions and base mutations for safety and efficacy.
The attenuated virus demonstrates safety and efficacy as a vaccine antigen, providing effective prevention and diagnosis of ASF, with a vaccine composition that suppresses infection occurrence and recurrence, and a diagnostic method that accurately detects the virus.
Smart Images

Figure KR2024007169_05122024_PF_FP_ABST
Abstract
Description
Attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 by cell adaptation and its use
[0001] The present invention relates to an African swine fever virus ASFV-KOR.INJE.MEC-01.2022 attenuated by cell adaptation and its use.
[0002]
[0003] This work was supported by the National Research Foundation of Korea's Science and Engineering Research Infrastructure Development Project (Project Number: 2021R1A6A1A03045495).
[0004] African swine fever (ASF) is a viral disease that affects only pigs and wild boars. After initial infection, symptoms typically appear within two to ten days. Common symptoms include decreased appetite, weakness, red skin, inflammation of the eye mucosa, vomiting, bloody diarrhea, and fever. Additionally, the skin may turn blue, areas of skin may die (black spots), hemorrhages may occur, and spontaneous abortions may occur in pregnant sows. ASF symptoms are similar to those of typical swine fever, and depending on the pathogenicity of the virus, between 30% and 100% of infected animals die.
[0005] ASF virus (ASFV) is a large, double-stranded DNA virus belonging to the Asfarviridae family. The DNA genome varies considerably from isolate to isolate, ranging from 160 to 210 kbp in length. The genome contains 150 to 167 open reading frames (OSFs) encoding 54 structural proteins of the ASFV particle and more than 100 infectious proteins (Dixon et al., 2013. Virus Res 173:3-14). To date, 24 genotypes have been identified.
[0006] There are currently no vaccines or treatments developed globally. ASFV is currently classified into 24 types, and the more types there are, the more difficult it is to develop a vaccine. With the recent increase in African swine fever cases worldwide, countries like the US and China are reportedly rushing to develop a vaccine, but commercialization is expected to take time. Currently, the disease is occurring in 53 countries worldwide, including 15 European countries, 29 African countries, and 9 Asian countries. In Asia, where the disease first emerged in China in August 2018, it has since been reported in Mongolia, Vietnam, Cambodia, Laos, Myanmar, the Philippines, and North Korea.
[0007] Meanwhile, Korean Patent Publication No. 2021-0065128 discloses an 'African swine fever virus vaccine' regarding a recombinant nucleic acid molecule comprising an expression cassette encoding a polyepitope comprising a T-cell antigen from a protein of African swine fever virus, and Korean Patent Publication No. 2021-0127887 discloses a polypeptide, a polynucleotide, a plasmid involved in generating an immune response to African swine fever, and an 'African swine fever vaccine composition' containing the same, but the 'African swine fever virus ASFV-KOR.INJE.MEC-01.2022 attenuated by cell adaptation and its use' of the present invention is not described.
[0008] The present invention was derived from the above-mentioned needs, and the inventors of the present invention confirmed that the African swine fever virus, which was being subcultured by infecting a cell line derived from rhesus monkey kidney cells during the process of developing a susceptible cell line of an African swine fever virus isolate (field strain), was transformed into an attenuated form, and confirmed that the naturally attenuated African swine fever virus was safe and effective as a vaccine strain, thereby completing the present invention.
[0009] To solve the above problem, the present invention provides an attenuated African swine fever virus, ASFV-KOR.INJE.MEC-01.2022, obtained by subculturing African swine fever virus in a cell line derived from rhesus monkey kidney cells.
[0010] In addition, the present invention provides a vaccine composition for preventing African swine fever, comprising the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 as an active ingredient.
[0011] In addition, the present invention provides a method for preventing African swine fever by administering the vaccine composition to a Suidae animal.
[0012] In addition, the present invention provides a kit for detecting African swine fever virus, comprising the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 as an active ingredient.
[0013] In addition, the present invention provides a method for diagnosing African swine fever infection, comprising a step of reacting the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 with immune serum isolated from a suspected African swine fever individual.
[0014] In addition, the present invention provides a method for producing a vaccine against African swine fever, comprising a step of subculturing the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 in a vaccine production cell line.
[0015] The naturally attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 according to the present invention has safety and efficacy, and thus can be usefully utilized as an antigen in a vaccine composition for preventing African swine fever.
[0016] Figure 1A shows the results of qPCR Ct values using the ASFVP72 gene to confirm the cell adaptation process of the ASFV isolate according to 18 passages after infecting and subculturing a domestic wild boar ASFV isolate (ASF / Korea / Wildbore / Inje-11893 / 2021) in the CA-CAS-01-A cell line. Figures 1B and 1C show the results of measuring the virus titer of a single vaccine candidate (ASFV-KOR.INJE.MEC-01.2022) at passage 18, which was finally obtained through a plaque assay in the CA-CAS-01-A cell line. B shows the TCID in the CA-CAS-01-A cell line. 50 (tissue culture infectious dose) is the result of confirming, and C is HAD in primary porcine macrophage 50 This is the result of confirming (median hemadsorption unit).
[0017] Figure 2 is a schematic diagram showing the genomic deletion region of ASFV-KOR.INJE.MEC-01.2022 (ASFV_MEC-01) produced from CA-CAS-01-A cell line infected with a domestic wild boar ASFV isolate (ASF / Korea / Wildbore / Inje-11893 / 2021).
[0018] Figure 3 is a schematic diagram of an animal experiment to evaluate the safety and efficacy of a vaccine candidate (ASFV-KOR.INJE.MEC-01.2022).
[0019] Figure 4 shows the results of confirming the survival rate of experimental animals for three weeks after two vaccinations with the vaccine candidate strain (ASFV-KOR.INJE.MEC-01.2022) at two-week intervals and challenge vaccination with ASFV_Hwacheon strain (domestic wild boar origin).
[0020] Figure 5 shows the results of observing changes in body temperature in experimental animals after vaccination and challenge with the vaccine candidate (ASFV-KOR.INJE.MEC-01.2022). Normal body temperature is between 38 and 39.5°C.
[0021] Figure 6 shows the results of antibody titer measurement using a multi-antigen indirect ELISA assay for the p32, p62, and p72 proteins of ASFV in animal experiments. A sample-to-positive (S / P) value of 30% or less is considered negative, a value between 30% and 40% is considered suspicious, and a value of 40% or more is considered positive.
[0022] In order to achieve the object of the present invention, the present invention provides an attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 (hereinafter, ASFV_MEC-01) obtained by subculturing African swine fever virus in a cell line derived from rhesus monkey kidney cells.
[0023] The attenuated African swine fever virus ASFV_MEC-01 of the present invention is characterized by having deletions in genes related to attenuation, and preferably MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-10L, MGF 110-14L, ASFV G ACD 00240, MGF 110-12L, MGF 110-13La, MGF 110-13Lb, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 360-8L partial, MGF 300-1L, MGF 300-2R, MGF 300-4L, MGF 110-8L partial, ASFV G ACD 00210, ASFV G ACD 00300, ASFV G ACD 00320, ASFV G ACD 00330, ASFV G ACD 00350, ASFV G ACD 00360 and X69R, and more preferably MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-10L, MGF 110-14L, ASFV G ACD 00240, MGF 110-12L, MGF 110-13La, MGF 110-13Lb, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 360-8L partial, MGF 300-1L, MGF These strains may include, but are not limited to, those in which all of the 300-2R, MGF 300-4L, MGF 110-8L partial, ASFV G ACD 00210, ASFV G ACD 00300, ASFV G ACD 00320, ASFV G ACD 00330, ASFV G ACD 00350, ASFV G ACD 00360 and X69R genes are all deleted.
[0024] In addition, the attenuated African swine fever virus ASFV_MEC-01 of the present invention is based on the ASFV Georgia 2007 / 1 genome sequence (GenBank: FR682468.2), wherein the 2,329th base adenine (A) is changed to guanine (G), the 7,059th base cytosine (C) is changed to thymine (T); the 26,425th and 27,200th base thymine (T) is changed to cytosine (C), the 44,576th base adenine (A) is changed to guanine (G); and the 72,295th, 72,315th, and 72,316th base guanine (G) is changed to adenine (A). Cytosine (C) at the 179,097th, 180,319th, 180,607th, 180,619th, 180,718th, 181,034th, 181,322nd, 181,809th, 181,891st, and 182,053rd bases is changed to thymine (T); It may additionally include substitutions (see Table 6), and the base mutations include the 106th amino acid leucine (Leu, L) of the MGF 360-1La protein being changed to proline (Pro, P), the 197th amino acid tryptophan (Trp, W) of the MGF 110-1L protein being changed to a stop codon, the 69th and 329th amino acids asparagine (Asn, N) of the MGF360-10L protein being changed to serine (Ser, S), the 323rd amino acid lysine (Lys, K) of the MGF 505-9R protein being changed to glutamic acid (Glu, E), and the 14th and 422nd amino acids methionine (Met, M) and alanine (Ala, A) of the MGF505-11L protein being changed to isoleucine (Ile, I) and threonine (Thr, T), respectively; The 96th and 100th amino acids aspartic acid (Asp, D) and glutamic acid (E) of the MGF 100-1L protein may be substituted with asparagine (N) and lysine (K), respectively, and the 86th amino acid alanine (A) of the MGF 100-3L protein may be substituted with threonine (T), but is not limited thereto.
[0025] The genome sequence of the attenuated African swine fever virus ASFV_MEC-01 according to one embodiment of the present invention may be composed of the base sequence of SEQ ID NO: 3.
[0026] The attenuated African swine fever virus ASFV_MEC-01 of the present invention is 1 x 10 in primary Porcine macrophages. 8 HAD 50 It is characterized by having a titer of / ㎖ or more.
[0027] Additionally, in the present invention, the cell line derived from the rhesus monkey kidney cells may be the CA-CAS-01-A cell line having the deposit number KCTC14568BP.
[0028] The present invention also provides a vaccine composition for preventing African swine fever, comprising the attenuated African swine fever virus ASFV_MEC-01 as an active ingredient.
[0029] In the vaccine composition of the present invention, the attenuated African swine fever virus ASFV_MEC-01 is as described above and has a genome consisting of the base sequence of sequence number 3.
[0030] The form of the vaccine composition according to the present invention may be selected from the group consisting of a live vaccine, an inactivated vaccine, a subunit vaccine produced using the gene of an attenuated African swine fever virus, a vector vaccine, a chimeric vaccine, a DNA vaccine, and an RNA vaccine, but is not limited thereto.
[0031] In the present invention, the term “prevention” means any act of suppressing or delaying the occurrence, spread, and recurrence of African swine fever infection by administering a vaccine composition according to the present invention.
[0032] Additionally, the vaccine composition of the present invention may further comprise a pharmaceutically acceptable carrier and / or adjuvant. Furthermore, in addition to the carrier, the vaccine composition of the present invention may further comprise an excipient and / or diluent.
[0033] The term "pharmaceutically acceptable" as used herein refers to a substance that is physiologically tolerable and does not typically cause allergic reactions such as gastrointestinal upset, dizziness, or similar reactions when administered to a mammal. Examples of such carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, and preservatives may be additionally included.
[0034] In addition, "adjuvant" as used herein means a pharmaceutical or immunological agent administered for the purpose of enhancing the immune response of a vaccine. The adjuvant may include aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), MF59, virosome, AS04 [a mixture of aluminum hydroxide and monophosphoryl lipid A (MPL)], AS03 (a mixture of DL-α-tocopherol, squalene, and polysorbate 80, an emulsifier), CpG, Flagellin, Poly I:C, AS01, AS02, ISCOMs, or ISCOMMATRIX.
[0035] The vaccine composition of the present invention can be formulated using methods known in the art to enable rapid, sustained, or delayed release of the active ingredient when administered to a mammal. Formulations include powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, and sterile powder forms.
[0036] The vaccine composition according to the present invention may be administered via various routes, including oral, parenteral, e.g., suppository, transdermal, intravenous, intraperitoneal, intramuscular, intralesional, nasal, and intrathecal administration. It may also be administered using an implantable device for sustained release, continuous, or repeated release. The frequency of administration may be once a day or divided into several doses within a desired range, and the administration period is not particularly limited.
[0037] The present invention also provides a method for preventing African swine fever by administering the vaccine composition to a Suidae animal.
[0038] In the method for preventing African swine fever according to the present invention, the pig animal may preferably be a wild boar (Sus) animal to which a domesticated species (Sus scrofa) belongs, but is not limited thereto.
[0039] The present invention also provides a kit for detecting African swine fever virus, comprising the attenuated African swine fever virus ASFV_MEC-01 as an active ingredient.
[0040] The above kit may include a reagent capable of detecting an attenuated African swine fever virus ASFV_MEC-01 according to the present invention and an antibody specifically binding to the attenuated African swine fever virus ASFV_MEC-01. In the kit of the present invention, the attenuated African swine fever virus ASFV_MEC-01 functions as an antigen, and the reagent for detecting the virus (antigen)-antibody complex may include, but is not limited to, a reagent for radial immunoassay, ELISA (Enzyme linked immunosorbent assay), or immunofluorescence analysis.
[0041] The present invention also provides a method for diagnosing African swine fever infection, comprising a step of reacting the attenuated African swine fever virus ASFV_MEC-01 with immune serum isolated from an animal suspected of having African swine fever.
[0042] The term "subject" used in the present invention means a mammal that has developed or may develop African swine fever infection, and may preferably include a pig or a wild boar.
[0043] The method for diagnosing African swine fever infection according to the present invention may comprise the step of reacting a sample (immune serum) isolated from a suspected African swine fever case with the African swine fever virus ASFV_MEC-01 of the present invention under conditions in which an antigen / antibody complex can be formed, and then detecting the formation of the antigen / antibody complex. The method for detecting the formation of the antigen / antibody complex can be performed using a method known in the art.
[0044] The present invention also provides a method for producing a vaccine against African swine fever, comprising a step of subculturing the attenuated African swine fever virus ASFV_MEC-01 in a vaccine production cell line.
[0045] In the manufacturing method of the present invention, the vaccine production cell line may preferably be the cell line CA-CAS-01-A deposited with the deposit number KCTC14568BP, but is not limited thereto, and there is no limitation on the type of cell as long as it is a cell in which the attenuated African swine fever virus ASFV_MEC-01 of the present invention can infect and proliferate.
[0046] In the manufacturing method of the present invention, the attenuated African swine fever virus ASFV_MEC-01 or an antigen derived therefrom can be converted into a physiologically acceptable form. This can be performed based on experience in manufacturing vaccines used for influenza vaccination. For the manufacture of vaccine injections, for example, the virus particles are lyophilized in 100 ml of phosphate-buffered saline (PBS) in the presence of 1% human albumin and 2% peptone in an ampoule, preferably a glass ampoule. Alternatively, the vaccine injections can be produced by sequential lyophilization of the virus in the formulation. The formulation may contain additional additives such as mannitol, dextran, sugar, glycine, lactose, or polyvinylpyrrolidone, or other adjuvants such as antioxidants or inert gases, stabilizers, or recombinant proteins suitable for in vivo administration (e.g., human serum albumin). The glass ampoule can then be sealed and stored at between 4°C and room temperature for several months. However, unless otherwise required, the ampoule can preferably be stored below -20°C.
[0047]
[0048] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.
[0049]
[0050] Materials and Methods
[0051] 1. Cells and viruses
[0052] The monkey kidney cell-derived CA-CAS-01-A cell line (accession number KCTC14568BP) was maintained in α-MEM (Invitrogen) medium containing 5% fetal bovine serum (FBS; Invitrogen) and antibacterial and antifungal solution (100x; Invitrogen) at 37°C in a humidified 5% CO2 incubator, with passages every 2–3 days. African swine fever virus (ASFV) was used as a domestic isolate (ASF / Korea / Wildbore / Inje-11893 / 2021) isolated from a wild boar outbreak in Inje, Gangwon-do in 2022, provided by the National Institute of Wildlife Disease Control and Prevention.
[0053]
[0054] 2. Serial passage of viruses
[0055] ASFV domestic isolate (ASF / Korea / Wildbore / Inje-11893 / 2021) was adapted to the CA-CAS-01-A cell line, and qPCR (quantitative PCR) was performed using a primer set specific for the ASFVP72 gene (Table 1). ASFV culture with a Ct value of 22 or less (Ct value: approximately 18) was used in the experiment.
[0056] ASFV infection medium was used as a serum-free medium, and 3-4 days after infection, it was replaced with the virus growth medium (serum-free medium) used for infection, and the previously sensitized virus was removed to confirm the proliferated virus. Subculture was performed at 7-day intervals after infection, and the culture fluids of the 1st, 3rd, 5th, and 10th passages were collected, the supernatants and cells were frozen at -80℃, and then thawed once in a 37℃ constant temperature water bath. qPCR was performed using the culture fluids to measure the Ct value, and a test to confirm intracytoplasmic infection (Alkaline Phosphatase assay_ASFV P30 detection; 1st antisera: Rabbit anti African swine fever virus phosphoprotein p30 antisera, 2nd antibody: Goat Anti-rabbit IgG H&L, Alkaline phosphate substrate kit: ImmPACT Vector RED) was performed. When ASFV positivity is confirmed, 2 ml of the first passage culture (1 x 10 6 CFU / ㎖) was used for the next passage together with 8㎖ of serum-free medium, and this was performed repeatedly.
[0057] Primer information used in qPCR Primer name Base sequence (5'→3') Sequence number P72_Forward CTG CTC ATG GTA TCA ATC TTA TCG A1 P72_Reverse GAT ACC ACA AGA TC(AG) GCC GT2
[0058]
[0059] 3. Virus titer measurement
[0060] In CA-CAS-01-A cell lines infected with ASFV isolates, culture supernatants were collected at the time point when 70% CPE (cytopathic effect) occurred after infection. For growth kinetics experiments, the supernatants were collected at different time points from cells infected with each virus strain and stored at -80°C. Virus titer was performed using the quantitative real-time RT-PCR method using the primer sets in Table 1. The quantitative real-time RT-PCR was performed under the following conditions: 1 cycle of 50°C for 2 minutes and 95°C for 10 minutes in the pretreatment process, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute in the main process.
[0061]
[0062] 4. Base sequence analysis
[0063] The full-length base sequence of cell-adapted ASFV was analyzed by request from Cellemics Co., Ltd.
[0064]
[0065] 5. Antibody titer confirmation (ELISA)
[0066] Antibody titers were measured by detecting P32, P62, and P72 of the ASF virus using ELISA. The measurement was performed using ID ScreenA. ®It was performed using African Swine Fever Indirect (ASF Elisa) kit (IDvet). Briefly, blood collected from the vaccinated and negative groups of experimental animals was centrifuged at 4,500 rpm for 10 minutes, and the supernatant (serum) was harvested. 190 μl of dilution buffer was added to each well, and 10 μl each of the negative control group to wells A1 and B1 and the positive control group to wells C1 and D1 was added. 10 μl of the serum samples harvested above were added to each of the remaining wells and incubated at 21°C (±5°C) for 45 minutes (±4 minutes). Afterwards, the reactants in each well were removed and washed three times with 300 μl of washing buffer. 100 μl of concentrated conjugate diluted 1 / 10 with dilution buffer was added to each well and incubated at 21°C (±5°C) for 30 minutes (±3 minutes). After removing the reactants from each well, the wells were washed three times with 300 μl of washing buffer, 100 μl of substrate solution was added to each well, and the wells were reacted for 15 minutes (±2 minutes) in the dark at 21°C (±5), 100 μl of reaction stop solution was added, and the absorbance was measured at 450 nm.
[0067] The validity of the reaction results is judged by the following criteria.
[0068] - The average OD value of the positive control substance is greater than 0.350 (ODPC > 0.350)
[0069] - The ratio of the average OD value of the positive control substance to the average OD value of the negative control substance is greater than 3. (ODPC / ODNC > 3)
[0070] - For each sample, the competitive percentage (S / P%) is calculated using the following formula:
[0071] S / P % = {(ODsample - ODNC) / (ODPC - ODNC)} x 100.
[0072] If the above S / P (sample-to-positive) value is 30% or less, it is judged as negative. If the S / P value is more than 30% but less than 40%, it is judged as suspicious. If the S / P value is 40% or more, it is judged as positive.
[0073]
[0074] 6. Pig infection experiment
[0075] In the present invention, in vivo pig research was conducted in a biosafety level 3 research facility within the Wildlife Disease Management Institute of the Ministry of Environment in accordance with the guidelines of the Institutional Animal Care and Use Committee.
[0076] The inventors of the present invention conducted animal experiments to confirm the attenuation (safety) and vaccine efficacy of the 18th passage ASF virus (ASFV-KOR.INJE.MEC-01.2022; ASFV_MEC-01) propagated and attenuated from the CA-CAS-01-A cell line. Briefly, >10 vaccine candidates were administered to 3-4 week-old pigs. 5 HAD 50 / ㎖ was administered twice at 2-week intervals via intramuscular injection, followed by ASFV_Hwacheonju (10 2 HAD 50 / ㎖) were challenged (Fig. 3). To determine the level of virus detection, oral swabs, rectal swabs, nasal swabs, serum, and whole blood samples were collected at 2-3 day intervals. In addition, body temperature changes, clinical symptoms, and survival rates were monitored for 3 weeks.
[0077]
[0078] 7. Statistical analysis
[0079] Student's t-test was used for all statistical analyses, and a P-value less than 0.05 was considered statistically significant.
[0080]
[0081] Example 1. Characterization of cell-adapted ASFV isolates
[0082] A domestic wild boar ASFV isolate (ASF / Korea / Wildbore / Inje-11893 / 2021) was infected with CA-CAS-01-A cell line (accession number KCTC14568BP) and passaged, and the cell adaptation process of the ASFV isolate was analyzed by qPCR using the ASFVP72 gene. As a result, as shown in Fig. 1A, the Ct value began to appear below 20 after the 5th passage, and the Ct value was confirmed to be below approximately 12 after the 16th passage. In addition, the results of measuring the virus titer of the single vaccine candidate (ASFV_MEC-01) at passage 18, which was finally obtained, through plaque assay in the CA-CAS-01-A cell line are shown in Table 2 below.
[0083]
[0084] In addition, the ASFV isolate (ASFV_MEC-01) cultured for a total of 18 passages was infected into CA-CAS-01-A cell line or primary porcine macrophage, and the virus proliferation according to the day was measured by TCID 50 (tissue culture infectious dose) or HAD 50 As confirmed by (median hemadsorption unit), it was confirmed that the proliferation of the virus did not decrease compared to the parent isolate after adaptive passage in the CA-CAS-01 cell line, but rather increased slightly (Fig. 1B, 1C).
[0085]
[0086] Example 2. Genomic analysis of cell-adapted ASFV isolates
[0087] In order to confirm the characteristics of the final secured vaccine candidate (ASFV_MEC-01), the virus was recovered from the culture solution cultured 18 times, and its genome sequence was analyzed. As a result, it was confirmed that a large gene deletion occurred in the 5' region, as shown in Fig. 2. The genes located in the deleted region are summarized in Table 3, and among the deleted genes, genes related to attenuation are summarized in Table 4. In addition, the positions of the deleted genes in Table 4 based on the sequence of African swine fever virus isolate ASFV Georgia 2007 / 1 genome assembly, complete genome: monopartite (GenBank: FR682468.2) are summarized in Table 5.
[0088]
[0089] Genome analysis results of the attenuated ASFV_MEC-01 virus Gene deleted Deletion site MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-10L, MGF 110-14L, ASFV G ACD 00240, MGF 110-12L, MGF 110-13La, MGF 110-13Lb, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 360-8L partial, MGF 300-1L, MGF 300-2R, MGF 300-4L, MGF 110-8L partial, ASFV G ACD 00210, ASFV G ACD 00300, ASFV G ACD 00320, ASFV G ACD 00330, ASFV G ACD 00350, ASFV G ACD 00360, X69RBold: Genes affecting attenuation
[0090]
[0091] In addition, in addition to the above genetic defects, a number of specific base mutations were identified in the genome sequence of the vaccine candidate strain ASFV_MEC-01 compared to the reference sequence (ASFV Georgia 2007 / 1 genome, GenBank: FR682468.2) and the genome sequence of the isolate (ASF / Korea / Wildbore / Inje-11893 / 2021).
[0092]
[0093] The vaccine candidate ASFV_MEC-01 of the present invention showed genetic stability (deleted site and point mutation location) up to 20 passages.
[0094]
[0095] Example 3. Safety and efficacy analysis of vaccine candidates
[0096] Animal testing was conducted to evaluate the safety (attenuation) and efficacy of the final secured vaccine candidate (ASFV_MEC-01).
[0097] The survival rate of experimental animals was checked for 3 weeks after being vaccinated twice with a vaccine candidate strain (ASFV_MEC-01) at a 2-week interval and challenged with ASFV_Hwacheon strain (derived from domestic wild boar). As a result, in the group that was not immunized with the vaccine candidate strain, one animal died on the 10th day after challenge, and all animals died on the 11th day, but the group immunized with the vaccine candidate strain showed a 100% survival rate (Fig. 4). In addition, the group immunized with the vaccine candidate strain did not show any fever symptoms during the vaccination period and after challenge and maintained normal body temperature, but in the non-vaccinated group, fever symptoms were observed to appear from the 4th day after challenge (Fig. 5). Furthermore, the antibody titer measurement results for the p32, p62, and p72 proteins of ASFV using a multi-antigen indirect ELISA analysis showed that the antibody titer gradually increased after the second vaccination with the vaccine candidate strain, turning positive one week after the second vaccination, and high antibody titers were confirmed up to 14 days after the challenge vaccination (Fig. 6). It is thought that such a high antibody titer contributed to the defense against ASFV_Hwacheon strain.
[0098] Based on the above results, it was determined that the ASF vaccine candidate strain ASFV-KOR.INJE.MEC-01.2022 (ASFV_MEC-01) of the present invention has both safety through natural attenuation and efficacy as a vaccine, and thus can be usefully utilized as an antigen for the development of an ASF vaccine.
Claims
1. Attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 obtained by subculturing African swine fever virus in a cell line derived from rhesus monkey kidney cells.
2. In the first paragraph, the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022, characterized in that the cell line derived from the rhesus monkey kidney cells is the CA-CAS-01-A cell line deposited as KCTC14568BP.
3. In paragraph 1, the attenuated African swine fever virus is MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-10L, MGF 110-14L, ASFV G ACD 00240, MGF 110-12L, MGF 110-13La, MGF 110-13Lb, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 360-8L partial, MGF 300-1L, MGF 300-2R, MGF 300-4L, MGF 110-8L partial, ASFV G ACD 00210, ASFV G ACD 00300, ASFV G ACD An attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022, characterized in that one or more genes selected from the group consisting of ASFV G ACD 00320, ASFV G ACD 00330, ASFV G ACD 00350, ASFV G ACD 00360 and X69R are deleted.
4. In the third paragraph, the attenuated African swine fever virus is MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-10L, MGF 110-14L, ASFV G ACD 00240, MGF 110-12L, MGF 110-13La, MGF 110-13Lb, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 360-8L partial, MGF 300-1L, MGF 300-2R, MGF 300-4L, MGF 110-8L partial, ASFV G ACD 00210, ASFV G ACD 00300, ASFV G ACD Attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 characterized by deletion of 00320, ASFV G ACD 00330, ASFV G ACD 00350, ASFV G ACD 00360 and X69R genes.
5. In paragraph 4, the attenuated African swine fever virus, based on the ASFV Georgia 2007 / 1 genome sequence, changes adenine (A) at the 2,329th base to guanine (G), cytosine (C) at the 7,059th base to thymine (T); thymine (T) at the 26,425th and 27,200th bases to cytosine (C), adenine (A) at the 44,576th base to guanine (G); and guanine (G) at the 72,295th, 72,315th, and 72,316th bases to adenine (A). An attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022, characterized in that it further comprises a mutation of cytosine (C) to thymine (T) at the 179,097th, 180,319th, 180,607th, 180,619th, 180,718th, 181,034th, 181,322nd, 181,809th, 181,891st, and 182,053rd bases.
6. A vaccine composition for preventing African swine fever, comprising the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 of any one of claims 1 to 5 as an active ingredient.
7. A vaccine composition according to claim 6, characterized in that the composition further comprises a pharmaceutically acceptable carrier or adjuvant.
8. A method for preventing African swine fever by administering the vaccine composition of Article 6 to a Suidae animal.
9. A kit for detecting African swine fever virus, comprising the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 of any one of clauses 1 to 5 as an active ingredient.
10. A method for diagnosing African swine fever infection, comprising a step of reacting the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 of any one of clauses 1 to 5 with immune serum isolated from an animal suspected of having African swine fever.
11. A method for producing a vaccine against African swine fever, comprising a step of subculturing the attenuated African swine fever virus ASFV-KOR.INJE.MEC-01.2022 of any one of claims 1 to 5 in a vaccine production cell line.
Citation Information
Patent Citations
fire extinguisher
FR682468A
Electronic device for determining whether to scan a channel of specific frequency band and method for the same
KR1020230045256A
Cards with antibacterial and anti-bias functions
KR102348341B1
Production method and detection method of african swine fever virus
EP4043030A1
Continuous stable cell line for identification of infectious african swine fever virus in clinical samples
US20210333293A1
